Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of anti-CD19 CAR-T cell therapy for B-cell hematologic malignancies, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD19 CAR-T therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: Chi Kong Li | Conditions: Lymphoma, Nonhodgkin, Leukemia, Lymphocytic | Phase 2 | Status: RECRUITING